Abstract
ADP-ribosylation (ADPr) is a posttranslational modification (PTM) of proteins that controls many cellular processes, including DNA repair, transcription, chromatin regulation and mitosis. A number of proteins catalyse the transfer and hydrolysis of ADPr, and also specify how and when the modification is conjugated to the targets. We recently discovered a new form of ADPr that is attached to serine residues in target proteins (Ser-ADPr) and showed that this PTM is specifically made by PARP1/HPF1 and PARP2/HPF1 complexes. In this work, we found by quantitative proteomics that histone Ser-ADPr is reversible in cells during response to DNA damage. By screening for the hydrolase that is responsible for the reversal of Ser-ADPr, we identified ARH3/ADPRHL2 as capable of efficiently and specifically removing Ser-ADPr of histones and other proteins. We further showed that Ser-ADPr is a major PTM in cells after DNA damage and that this signalling is dependent on ARH3.
Article and author information
Author details
Funding
Wellcome (101794)
- Ivan Ahel
Cancer Research UK (C35050/A22284)
- Ivan Ahel
Deutsche Forschungsgemeinschaft (EXC 229)
- Ivan Matic
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Ivan Dikic, Goethe University Frankfurt, Germany
Publication history
- Received: May 11, 2017
- Accepted: June 23, 2017
- Accepted Manuscript published: June 26, 2017 (version 1)
- Accepted Manuscript updated: June 29, 2017 (version 2)
- Version of Record published: August 10, 2017 (version 3)
Copyright
© 2017, Fontana et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,859
- Page views
-
- 643
- Downloads
-
- 72
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.